EGFR Inhibition with Cetuximab in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)


EGFR Inhibition with Cetuximab in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Harold J Burstein, MD, PhD (12/22/10)

Baselga J et al. Cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, HER2-negative (triple-negative) metastatic breast cancer: Results of the randomized phase II BALI-1 trial. San Antonio Breast Cancer Symposium 2010;Abstract PD01-01.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.